Skip to search formSkip to main contentSkip to account menu

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

View on PubMed (opens in a new tab)

Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

The expression of prostate-specific membrane antigen (PSMA) is increased in prostate cancer. Recently, 68Ga-PSMA (Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]) was developed as a PSMA ligand. The aim of…
View on Publisher (opens in a new tab)

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

View on PubMed (opens in a new tab)

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

A molecular imaging TNM system (miTNM, version 1.0) is proposed as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI, designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions.
View on Publisher (opens in a new tab)

Current use of PSMA–PET in prostate cancer management

In patients with primary prostate cancer of intermediate-risk to high-risk, PSMA-based imaging has been reported to improve detection of metastatic disease compared with CT or mpMRI, rendering additional cross-sectional imaging or bone scintigraphy unnecessary.
View on Nature (opens in a new tab)

Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

View on PubMed (opens in a new tab)

CpG‐DNA aided cross‐presentation of soluble antigens by dendritic cells

It is shown that CpG‐DNA ovalbumin (OVA) conjugates trigger in vivo peptide‐specific CTL responses at tenfold lower Ag doses compared to a mixture of Cpg‐DNA plus OVA.
View on Wiley (opens in a new tab)

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it.
View on Springer (opens in a new tab)

Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer

The results indicate that BS in patients who have received PSMA PET for staging only rarely offers additional information; however, prospective studies, including a standardized integrated x-ray computed tomography (SPECT/CT) protocol, should be performed in order to confirm the presented results.
View on Springer (opens in a new tab)

Patients with Biochemical Recurrence After Radical Prostatectomy

were 96.8%, 93.0%, 72.7%, and 57.9% for PSA levels of $2, 1 to ,2, 0.5 to ,1, and 0.2 to ,0.5 ng/mL, respectively. Whereas detection rates increased with a higher PSA velocity (81.8%, 82.4%, 92.1%,…
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)